


Patent claims

1. Compounds of the general formula (I):

5



wherein


10

A is a heteroalkyl-, heterocycloalkyl-, heteroalkyl-cycloalkyl-, heteroaryl- or heteroarylalkyl group,

15

U is hydrogen, a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroaryl-alkyl group,

G-E is selected from the following groups,



20

or is part of an optionally substituted phenyl ring,

V-W is a group of the formula CH-CH or C=C (cis or trans),

25

R¹ is a C₁-C₄ alkyl- or a C₃-C₄-cycloalkyl group,

X is oxygen or a group of the formula NR², wherein R² is hydrogen, a alkyl-, alkenyl-, alkynyl-, hetero-

alkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl group,

5 Y is oxygen or a group of the formula NR^{10} , wherein R^{10} is hydrogen, oxygen, a OH, NH_2 , alkyl- or a heteroalkyl group (as for example a alkyloxy-, alkyl-amino- or dialkylamino group).



10 R^3 and R^4 are independently of each other hydrogen, a C_1 - C_4 alkyl group or together are part of a cycloalkyl group with 3 or 4 ring atoms,

R^9 is hydrogen, a alkyl-, alkenyl-, alkynyl-,
15 heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl group,

or a pharmacologically acceptable salt, solvate,
20 hydrate or a pharmacologically acceptable formulation thereof.

2. Compounds according to claim 1, wherein A is a group of the formula $-\text{C}(\text{CH}_3)=\text{CHR}^5$ or $-\text{CH}=\text{CHR}^5$, wherein R^5 is
25 a heteroaryl- or a heteroarylalkyl group.

3. Compounds according to claim 1, wherein A is a group of the general formula (II) or (III):



30

wherein

Q a sulphur, oxygen or a group of the formula NR^7 wherein R^7 is hydrogen, a C_1 - C_4 alkyl group or a C_1 - C_4 -

heteroalkyl group, z is nitrogen or a CH group and R⁶ is a group of the formula OR⁸ or NHR⁸, a alkyl-, alkenyl, alkynyl- or a heteroalkyl group, wherein R⁸ is hydrogen, a C₁-C₄-alkyl group or a C₁-C₄-heteroalkyl group.

4. Compounds according to claim 3, wherein z is a CH-group.

5. Compounds according to claim 3 or 4, wherein Q is sulphur or oxygen.

6. Compounds according to the claims 3 to 5, wherein R⁶ is a group of the formula CH₃, CH₂OH or CH₂NH₂.

7. Compounds according to the claims 1 to 6, wherein X is oxygen.

8. Compounds according to the claims 1 to 7, wherein R¹ is a methyl group.

9. Compounds according to the claims 1 to 8, wherein R³ and R⁴ are methyl groups.

10. Compounds according to the claims 1 to 9, wherein U is hydrogen.

11. Compounds according to the claims 1 to 10, wherein R⁹ is hydrogen.

12. Compounds according to the claims 1 to 11, wherein Y is oxygen or a group of the formula NH, NOH or NO.

13. Pharmaceutical compositions containing a compound according to any one of the claims 1 to 12 and optionally carrier and/or adjuvants.

14. Use of a compound or a pharmaceutical composition according to any one of the preseding claims 1 to 13 for the treatment of cancer diseases.

Summary

The present invention relates to new macrocycles of the
5 general formula (I) as well as their use for the treatment
of cancer diseases.

